BGE-102 has the potential for therapeutic retinal exposure with oral delivery, reducing treatment burden in ocular indications currently treated with intravitreal therapies Growing preclinical and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback